Atlas market file · Equity · United States
Cerus CorpCERS
- Last close
- 2.32
- Change
- +2.20%
- 96-bar range
- 1.68 – 3.47
- As of
- 6 Aug 2026
Cerus Corp is a surgical & medical instruments & apparatus issuer listed as CERS on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
CERS
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-0.43% over the window).
Source rail: Yahoo Finance chart API (CERS). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CERS. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CERS public profile
Surgical & medical instruments & apparatus issuer. Cerus Corp is connected to current market context, cited company sources and its retained research file.
Cerus Corp trades as CERS on NASDAQ. Cerus Corp (CERS) has a latest verified close of 2.32, up 2.20%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CERS under USA Stocks for browsing.
What changed for Cerus Corp today
Cerus Corp (CERS) closed July 2026 with a mixed bloodwork report: Q1 2026 revenue rose 24% year-over-year to $53.7M, but the company bled $1.6M in net losses and saw inventory swell to $61.1M, a $5.8M increase. The INTERCEPT Blood System remains the crown jewel, but the balance sheet suggests a kingdom running on red fumes.
The company, which claims to be ‘dedicated solely to safeguarding the world’s blood supply,’ operates in a niche market with high regulatory barriers. Its INTERCEPT platform aims to pathogen-reduce blood products, a critical tool in regions with elevated disease risks. However, the latest 10-Q shows operating cash flow turned negative (-$3.0M), raising questions about how long this life sciences play can sustain its current transfusion of cash.
Upcoming catalysts include Q2 2026 earnings on July 30 and a four-year supply deal with France’s Établissement Français du Sang. But with liabilities ($154.6M) nearly doubling stockholders’ equity ($67.6M), the source directs readers to for any signs of operational triage. The company’s ISBT Congress presentation in Kuala Lumpur may tout ‘global experience,’ but the real test lies in turning inventory into cash before the fiscal defibrillator kicks in.
The stock’s 194.1M diluted share count and consistent inventory build ($5.8M quarterly increase) suggest management is either prepping for a demand surge or playing a high-stakes game of blood bank musical chairs. With negative operating cash flow and a pending earnings release, the market will soon learn whether Cerus can stabilize its financial vital signs.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CERS technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CERS
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CERS research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CERS FAQ
What is Cerus Corp (CERS)?Cerus Corp (CERS) has a latest verified close of 2.32, up 2.20%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks...
Cerus Corp (CERS) has a latest verified close of 2.32, up 2.20%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CERS?Cerus Corp (CERS) has a latest verified close of 2.32, up 2.20%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the...
Cerus Corp (CERS) has a latest verified close of 2.32, up 2.20%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CERS under USA Stocks for browsing.
How often is the CERS page updated?The CERS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CERS public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CERS?The CERS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CERS. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The CERS file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CERS. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CERS?Yes. The workstation can open CERS, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CERS, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CERS page investment advice?No. The CERS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CERS page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →